FGF21 and obesity due to melanocortin 4 receptor deficiency: Exogenous FGF21 administration counteracts obesity in several different animal models [10,11,12,13], and clinical trials have already been conducted in obese human patients utilizing an FGF21 variant, LY2405319 [14,15].